Navigation Links
ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development
Date:9/22/2008

MEMPHIS, Tenn., Sept. 22 /PRNewswire/ -- Accelerated Community Oncology Research Network (ACORN) (TM), a national oncology-focused Contract Research Organization (CRO) and clinical trial network, announced today that it has named Tara Webb as Senior Director of Business Development. Webb brings a successful record of establishing and cultivating CRO relationships. "Tara Webb has an exceptional background of work in the CRO field and is widely respected for her industry knowledge, capabilities and integrity," remarked Edward J. Stepanski, PhD, Chief Operations Officer of ACORN. "Her responsibilities at ACORN CRO will include presenting ACORN's capabilities to pharmaceutical companies and emerging biotechs, forging alliances with key accounts and providing customer service oversight on behalf of clients." Most recently, Webb served as Senior Director, Business Development for i3 Statprobe, where she was responsible for developing new business opportunities and strengthening current client relationships both nationally and internationally.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/CLM151LOGO )

ACORN CRO will provide Webb with the platform to focus her energies exclusively in the field of oncology, thus enabling closer working relationships with a select group of sponsors. "Tara Webb is an excellent fit with our organization as she is known for her dedication and determination to consistently provide her clients and their projects with uncompromising standards of quality," stated Steve Coplon, ACORN CEO. "With a decade of research experience augmented by a strong, technological background, she will provide excellent representation of ACORN CRO's scientific strength, unprecedented community oncology relationships, and ACORN's proprietary technology, including Guardian EDC(TM)," added Coplon.

Webb holds a M.S. in Organizational Leadership & Administration and a B.S. in Health Administration (Accelerated Program) from Concordia College, Ann Arbor, Michigan.

About ACORN CRO

ACORN CRO provides a full range of research services to sponsors, from clinical trial design to site selection to the results phase with bioanalysis and findings presentation. Exclusively focused on oncology, ACORN CRO is backed by scientists and medical professionals dedicated to advancing cancer care through research. An important added strength resides in ACORN's network of community oncology researchers, specifically selected for their commitment to oncology research and excellence in its execution. ACORN, Inc., a privately held company, significantly enhances the speed, accuracy, and productivity of conducting clinical research in the community oncology setting. Proactive project management with focused teams of clinical experts achieves these goals. Well-defined processes augmented by proprietary technology provide oversight and efficiencies on study functions for both pharma and participating sites.

Webb can be reached at twebb@sosacorn.com or (901) 435-5570.

For additional information, contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878 or visit http://www.ACORNresearch.net .

Accelerated Community Oncology Research Network, Inc. (TM) (ACORN) ACORN focuses on oncology exclusively. ACORN offers centralized clinical trial services, scientific analysis, and is a full-service Contract Research Organization (CRO), providing contract and budgeting services; fostering accrual of subjects at the site level; collecting data and monitoring its accuracy; and working seamlessly with both trial sponsors and participating practices.

Contact Information:

Liz Conway

(901) 435-5570

lconway@sosacorn.com

http://www.ACORNresearch.net

Deborah D. Coble

901-683-0055x1312

dcoble@sosacorn.com


'/>"/>
SOURCE Accelerated Community Oncology Research Network
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse
2. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
3. Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts
6. Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers
7. Therapure Biopharma Inc. opens for business with first client contracts
8. BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts
9. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
10. Sales Contracts Worth $2.3 Million Signed Since 1 July 2008
11. [video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.nets 3-Minute Press Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):